By Michele Maatouk
Date: Thursday 15 May 2025
LONDON (ShareCast) - (Sharecast News) - Shares in Hikma Pharmaceuticals surged on Thursday as investors welcomed new medium-term guidance from the company.
Alongside a sell-side analysts and investors even at its manufacturing and R&D facility in Columbus, Ohio, the pharmaceuticals group said that for group revenue, it expects a three-year compound annual growth rate of 6% to 8% between 2024 and 2027.
For operating profit, it expects a three-year compound annual growth rate of 7% to 9%.
In addition, Hikma said introduced a five-year target for group revenue to reach $5bn by 2030.
At 1235 BST, the shares were up 8.1% at 2,098p.
Email this article to a friend
or share it with one of these popular networks:
Currency | UK Pounds |
Share Price | 1,775.00p |
Change Today | 2.00p |
% Change | 0.11 % |
52 Week High | 2,340.00p |
52 Week Low | 1,592.00p |
Volume | 422,168 |
Shares Issued | 221.89m |
Market Cap | £3,938.48m |
RiskGrade | 125 |
Value |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Growth |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Strong Buy | 7 |
Buy | 3 |
Neutral | 2 |
Sell | 0 |
Strong Sell | 0 |
Total | 12 |
Latest | Previous | |
---|---|---|
Interim | Final | |
Ex-Div | 14-Aug-25 | 20-Mar-25 |
Paid | 18-Sep-25 | 01-May-25 |
Amount | 36.00¢ | 48.00¢ |
Time | Volume / Share Price |
17:03 | 6,211 @ 1,765.94p |
16:38 | 830 @ 1,775.00p |
16:35 | 146 @ 1,775.00p |
16:35 | 420 @ 1,775.00p |
16:35 | 230,828 @ 1,775.00p |
You are here: research